Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for Relapsed/Refractory Non-Hodgkin Lymphoma
NCT03196830Phase 2Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2017
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Beijing Boren Hospital autologous CAR-T therapy in non-Hodgkin lymphoma (NHL), sponsored by First Affiliated Hospital of Soochow University. Started Jun 2017; status: completed.
02
Drugs
Beijing Boren Hospital autologous CAR-T therapy
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03196830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196830.